Expand SILO Menu
SILO MENU

SILO Latest Press Releases

-- September 18, 2026 --

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio Globe Newswire 8:50 AM

-- September 9, 2026 --

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum Globe Newswire 9:15 AM

-- August 18, 2026 --

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment Globe Newswire 4:15 PM

-- August 10, 2026 --

Silo Pharma Granted European Patent Covering Novel PTSD Therapy Globe Newswire 8:15 AM

-- August 6, 2026 --

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform Globe Newswire 8:50 AM

-- July 21, 2026 --

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program Globe Newswire 8:55 AM

-- July 14, 2026 --

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform Globe Newswire 8:55 AM

-- July 10, 2026 --

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Globe Newswire 8:00 AM

-- July 7, 2026 --

Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program Globe Newswire 8:11 AM

-- June 29, 2026 --

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request Globe Newswire 4:15 PM

-- June 23, 2026 --

Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial Globe Newswire 8:17 AM

-- June 18, 2026 --

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire 8:12 AM

-- May 7, 2026 --

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury Globe Newswire 8:05 AM

-- April 29, 2026 --

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD Globe Newswire 9:08 AM
Market Data Delayed 15 Minutes